J&J announces 22 partnerships
The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled 22 new collaborations spanning the cancer, diabetes, rare diseases and consumer healthcare sectors. The Innovation unit also said it will start an external collaboration program to accelerate the development of select candidates.
Several of the collaborations, which include both public and private partnerships, focus on identification of disease biomarkers. J&J's Janssen Pharmaceuticals Inc. unit will collaborate with the Institute for Systems Biology (Seattle, Wash.) to identity markers of diabetes progression in beta cells, and its Janssen Biotech Inc. unit will identify biomarkers of prostate and lung cancer with the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (Cambridge, Mass.). ...